Evidence map›Paper›PMID 19285068›Full record

ArticleExperimental cell research2009

Role of Ceacam1 in VEGF induced vasculogenesis of murine embryonic stem cell-derived embryoid bodies in 3D culture.

Angel Gu, Walter Tsark, Kathryn V Holmes, John E Shively

Open access · greenAbstract read
In one paragraph

Article in Experimental cell research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. CEACAM1 in vascular homeostasis and inflammation.European journal of clinical investigation · 2024
    Review
  4. Article
  5. The role of nuclear factor kappa B (NF-κB) in filarial pathology.Journal of cell communication and signaling · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Angel GuDepartment of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
Walter Tsark
Kathryn V Holmes
John E Shively
Beckman Research InstituteCity of Hope · USCity Of Hope National Medical Center · USUniversity of Colorado Health · US

Funding

Virus Propagation and InoculationP01AI059576 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLMES, KATHRYN V · 2004 to 2009
$9.0M
Role of CEACAM1 in Epithelial Cell PolarizationR01CA084202 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI SHIVELY, JOHN ERNEST · 2000 to 2010
$4.1M
NCI NIH HHS CA84202NCI NIH HHS R01 CA084202NIAID NIH HHS AI059576NIAID NIH HHS P01 AI059576
6 · The paper itself

Abstract

CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1), a type I transmembrane glycoprotein involved in cell-cell adhesion has been shown to act as an angiogenic factor for mouse and human endothelial cells. Based on the ability of CEACAM1 to initiate lumen formation in human mammary epithelial cells grown in 3D culture (Matrigel), we hypothesized that murine CEACAM1 may play a similar role in vasculogenesis. In order to test this hypothesis, murine embryonic stem (ES) cells stimulated with VEGF were differentiated into embryoid bodies (EB) for 8 days (-8-0 d) and transferred to Matrigel in the presence or absence of anti-CEACAM1 antibody for an additional 12 days (0-12 d). In the absence of anti-CEACAM1 antibody or in the presence of an isotype control antibody, the EB in Matrigel underwent extensive sprouting, generating lengthy vascular structures with well-defined lumina as demonstrated by confocal microscopy, electron microscopy, and immunohistochemical analysis. Both the length and architecture of the vascular tubes were inhibited by anti-CEACAM1 mAb CC1, a mAb that blocks the cell-cell adhesion functions of CEACAM1, thus demonstrating a critical role for this cell-cell adhesion molecule in generating and maintaining vasculogenesis. QRT-PCR analysis of the VEGF treated ES cells grown under conditions that convert them to EB revealed expression of Ceacam1 as early as -5 to -3 d reaching a maximum at day 0 at which time EBs were transferred to Matrigel, thereafter levels at first declined and then increased over time. Other markers of vasculogenesis including Pecam1, VE-Cad, and Tie-1 were not detected until day 0 when EBs were transferred to Matrigel followed by a steady increase in levels, indicating later roles in vasculogenesis. In contrast, Tie-2 and Flk-1 (VEGFR2) were detected on day five of EB formation reaching a maximum at day 0 on transfer to Matrigel, similar to Ceacam1, but after which Tie-2 declined over time, while Flk-1 increased over time. QRT-PCR analysis of the anti-CEACAM1 treated ES cells revealed a significant decrease in the expression of Ceacam1, Pecam1, Tie-1, and Flk-1, while VE-Cad and Tie-2 expression were unaffected. These results suggest that the expression and signaling of CEACAM1 may affect the expression of other factors known to play critical roles in vasculogenesis. Furthermore this 3D model of vasculogenesis in an environment of extracellular matrix may be a useful model for comparison to existing models of angiogenesis.

Indexed as

AnimalsAntibodies, MonoclonalBiomarkersBlood CellsBlotting, WesternCarcinoembryonic AntigenCell Culture TechniquesCollagenDrug CombinationsEmbryo, MammalianEmbryonic Stem CellsEndotheliumFemaleGene Expression Regulation, DevelopmentalImmunohistochemistryLamininAntibodies, MonoclonalBiomarkersCarcinoembryonic AntigenCeacam1 protein, mouseCollagenDrug CombinationsLamininmatrigelProtein IsoformsProteoglycansRNA, MessengerVascular Endothelial Growth Factor A

Identifiers

PMID19285068
PMCPMC2745895
OpenAlexW2094388293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.